Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651729 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT00651729 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 279 participants.
The verdict
NCT00651729, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
Interventions
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651729
The ClinicalTrials.gov registry entry for NCT00651729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin Type A is the first listed.
NCT00651729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651729 about?
NCT00651729 is a clinical study titled "Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity". The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
What is the current status of trial NCT00651729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2003-04. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00651729?
The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00651729?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.